Compare ARDX & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | WEN |
|---|---|---|
| Founded | 2007 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2014 | 2000 |
| Metric | ARDX | WEN |
|---|---|---|
| Price | $6.97 | $6.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 22 |
| Target Price | ★ $15.14 | $8.84 |
| AVG Volume (30 Days) | 3.8M | ★ 7.4M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 8.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.85 |
| Revenue | $2,607,000.00 | ★ $2,176,891,000.00 |
| Revenue This Year | $37.75 | $2.26 |
| Revenue Next Year | $34.24 | $0.94 |
| P/E Ratio | ★ N/A | $7.79 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $6.37 |
| 52 Week High | $8.40 | $12.52 |
| Indicator | ARDX | WEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 45.87 |
| Support Level | $6.83 | $6.73 |
| Resistance Level | $8.23 | $7.28 |
| Average True Range (ATR) | 0.36 | 0.24 |
| MACD | 0.11 | -0.02 |
| Stochastic Oscillator | 69.88 | 42.63 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.